注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Summit Therapeutics Inc是一家生物制药公司。该公司致力于发现、开发和商业化治疗严重传染病的新型抗生素。其主要的传染病艰难梭菌感染(CDI)候选产品是ridinilazole,是一种口服小分子抗生素。该公司的临床前候选药物包括来自DDS-04系列的SMT-738,用于开发对抗耐多药感染,特别是耐碳青霉烯肠杆菌(CRE)感染。该公司正在进行一项三期临床项目,重点是CDI。该公司还寻求通过使用其专有的Discuva平台开发新机制、精准抗生素来扩大其候选产品组合。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Francesco Muntoni | - | - | Member of Scientific Advisory Board |
Edith Sim | - | - | Member of Scientific Advisory board |
Bob Sim | - | - | Member of Scientific Advisory board |
Roger Patient | - | - | Member of Scientific Advisory Board |
Derek Stemple | - | - | Member of Scientific Advisory board |
William Graham Richards | 84 | - | Member of Scientific Advisory board |
Jean-Paul Vincent | - | - | Member of Scientific Advisory board |
Marcel van den Heuvel | - | - | Member of Scientific Advisory Board |
Ujwala Mahatme | 58 | 2020 | Independent Non-Executive Director |
Yu Xia | 56 | 2023 | Director |
Mahkam Zanganeh | 54 | 2020 | Co-CEO, President & Director |
Robert W. Duggan | 79 | 2019 | Co-CEO & Executive Chairman |
Kenneth A. Clark | 65 | 2021 | Lead Independent Director |
Robert F. G. Booth | 70 | 2022 | Independent Director |
Alessandra Cesano | 63 | 2022 | Independent Non-Executive Director |
Dame Kay Davies | 73 | - | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
Manmeet Singh Soni | 46 | 2019 | COO, CFO & Director |
Mostafa Ronaghi | 55 | 2024 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核